ATE418612T1 - Anthrax-impfstoff - Google Patents

Anthrax-impfstoff

Info

Publication number
ATE418612T1
ATE418612T1 AT99941953T AT99941953T ATE418612T1 AT E418612 T1 ATE418612 T1 AT E418612T1 AT 99941953 T AT99941953 T AT 99941953T AT 99941953 T AT99941953 T AT 99941953T AT E418612 T1 ATE418612 T1 AT E418612T1
Authority
AT
Austria
Prior art keywords
anthrax vaccine
aureus
intoxication
subjects
inducing
Prior art date
Application number
AT99941953T
Other languages
English (en)
Inventor
John Lee
Peter Pushko
Michael Parker
Jonathan Smith
Susan Welkos
Original Assignee
U S Medical Res Inst Of Infect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Medical Res Inst Of Infect filed Critical U S Medical Res Inst Of Infect
Application granted granted Critical
Publication of ATE418612T1 publication Critical patent/ATE418612T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT99941953T 1998-07-10 1999-07-09 Anthrax-impfstoff ATE418612T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
ATE418612T1 true ATE418612T1 (de) 2009-01-15

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943610T ATE443768T1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung
AT99941953T ATE418612T1 (de) 1998-07-10 1999-07-09 Anthrax-impfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99943610T ATE443768T1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung

Country Status (7)

Country Link
US (2) US6632640B1 (de)
EP (2) EP1097213B1 (de)
AT (2) ATE443768T1 (de)
AU (2) AU758019B2 (de)
CA (2) CA2339355A1 (de)
DE (2) DE69941454D1 (de)
WO (2) WO2000002523A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
ATE443768T1 (de) * 1998-07-10 2009-10-15 U S Medical Res Inst Of Infect Impfstoff gegen staphylokokken-vergiftung
MXPA01001631A (es) * 1998-08-13 2002-04-08 Walter Reed Army Inst Of Res D Vacunas de superantigenos bacterianos.
JP2002541934A (ja) 1999-04-16 2002-12-10 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 二重チャンバー式貯蔵器を備えている薬物供給装置
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) * 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
CA2469671A1 (en) * 2001-12-05 2003-06-12 Rakesh Bhatnagar A process for the preparation of a non-toxic anthrax vaccine
AU2003224265A1 (en) * 2002-04-11 2003-10-27 Powderject Research Limited Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
EP1670505B1 (de) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna-promotor und anthrax-vakzine
US8409590B2 (en) 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
BR122016029840B1 (pt) 2004-09-22 2021-10-13 Glaxosmithkline Biologicals S.A. Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
WO2006113214A2 (en) * 2005-04-11 2006-10-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Vaccine against pandemic strains of influenza viruses
CN101252932B (zh) 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
WO2008156829A2 (en) * 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US9789176B2 (en) * 2011-03-16 2017-10-17 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013025834A2 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
DK3010535T3 (da) * 2013-06-19 2020-11-30 Integrated Biotherapeutics Inc Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf
CN109195988B (zh) 2016-01-10 2023-12-01 尼奥克斯医疗有限公司 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
CN110996993B (zh) 2017-07-27 2024-05-31 Ab疫苗公司 包含源自超抗原类毒素的融合肽的免疫原性组合物
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626805A4 (en) * 1992-01-28 1995-12-06 Nat Jewish Ct Immun & Respirat Protective effects of mutated superantigens.
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
JP4422330B2 (ja) * 1998-02-15 2010-02-24 財団法人化学及血清療法研究所 新規な免疫異常性疾患予防・治療用剤
EP1092031A2 (de) * 1998-06-29 2001-04-18 U.S. Medical Research Institute of Infectious Diseases Marburg-virus impfstoffe
ATE443768T1 (de) * 1998-07-10 2009-10-15 U S Medical Res Inst Of Infect Impfstoff gegen staphylokokken-vergiftung
MXPA01001631A (es) * 1998-08-13 2002-04-08 Walter Reed Army Inst Of Res D Vacunas de superantigenos bacterianos.
AU771774B2 (en) * 1998-12-07 2004-04-01 U.S. Medical Research Institute Of Infectious Diseases Live attenuated Venezuelan equine encephalitis vaccine

Also Published As

Publication number Publication date
EP1097213B1 (de) 2009-09-23
WO2000002522A9 (en) 2001-04-05
EP1097212A2 (de) 2001-05-09
DE69941454D1 (de) 2009-11-05
EP1097212B1 (de) 2008-12-24
EP1097213A2 (de) 2001-05-09
WO2000002522A3 (en) 2000-10-12
DE69940157D1 (en) 2009-02-05
WO2000002523A2 (en) 2000-01-20
CA2339355A1 (en) 2000-01-20
ATE443768T1 (de) 2009-10-15
US6632640B1 (en) 2003-10-14
WO2000002523A9 (en) 2000-07-27
WO2000002523A3 (en) 2000-11-23
WO2000002522A2 (en) 2000-01-20
CA2337966A1 (en) 2000-01-20
US7374931B2 (en) 2008-05-20
AU761021B2 (en) 2003-05-29
AU5667399A (en) 2000-02-01
US20040009183A1 (en) 2004-01-15
AU758019B2 (en) 2003-03-13
AU5542699A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
ATE418612T1 (de) Anthrax-impfstoff
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
EA200100565A1 (ru) Новые стрептококковые антигены
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
WO2004075829A3 (en) Adjuvanted influenza vaccine
DK1565478T3 (da) Polysaccharidvaccine mod stafylokokinfektioner
BR0200294B1 (pt) sistema e mÉtodo de processamento de algodço.
WO2002034773A3 (en) Streptococcal genes
DK1625393T3 (da) Vacciner, som medfører beskyttelse mod infektion af Streptococcus pneumonia
BR0115646A (pt) Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE270112T1 (de) Streptococcus equi impfstoff
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
BR0013574A (pt) Antìgeno vacina de moraxella
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
AR039035A1 (es) Proteinas con dominios tipo ig bacterianos (big) presentes en especies de leptospira
UA25233A (uk) Спосіб профілактики сибірки у твариh
ITMI20031872A1 (it) Copolimeri di poliesteri e polivinilpirrolidone.
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties